ImmunoCellular Therapeutics (OTC:IMUC) said Monday its chief executive Manish Singh will make a presentation at a health care conference today.
The company, which is headquartered in Los Angeles, is seeking to
develop and commercialize new therapeutics to fight cancer using the
Singh will present at the Cowen and Company’s 32nd Annual Health Care
symposium taking place in Boston, Massachusetts today at 2:10 p.m. The
event will be on the fourth floor at the Salon C of the Marriot Hotel.
The presentation will be webcast here: http://wsw.com/webcast/cowen6/imuc/
ImmunoCellular’s lead product candidate ICT-107 is currently in a
randomized phase II trial at multiple centres in the U.S. ICT-107 is a
dendritic cell-based vaccine that works by activating a patient's immune
system against specific tumour associated antigens for glioblastoma
multiforme, an aggressive type of brain cancer.
This is done by removing dendritic cells from a patient, loading them
with the tumour-related antigens, and re-injecting them back into the
patient's body to trigger an immune response against cancer cells
exhibiting these antigens.
Rather than simply targeting a single tumour-specific antigen,
ImmunoCellular's vaccine pursues multiple different antigens found on
cancer stem cells.
Cancer stem cells are thought to be the originators of common tumour
cells, and lead to cancer’s re-growth after chemotherapy. It is believed
that destroying the cancer stem cells will allow for longer survival,
The company’s share price rose 3.27 percent to $2.84 on the OTC, or over-the-counter market Monday afternoon.